Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bentrio (AM-301) is a preservative-free, drug-free nasal spray developed by Altamira Therapeutics and licensed to Nuance Pharma for the Greater China market. It is designed to protect against airborne allergens and viruses. The formulation contains ectoine, a natural extremolyte that forms a protective hydration film (the Ectoin Hydro Complex) on the nasal mucosa. This physical barrier traps inhaled particles such as pollen, house dust mites, and viruses (including SARS-CoV-2 and influenza), preventing them from contacting and infecting the nasal epithelium. By providing a mechanical shield and moisturizing the nasal lining, Bentrio alleviates allergic symptoms and reduces the risk of viral respiratory infections. It is classified as a medical device in several jurisdictions due to its physical mode of action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ectoine.